Telomir Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), an emerging growth company incorporated in Florida, filed this Current Report on Form 8-K on December 16, 2024. The filing addresses a change in the registrant's certifying accountant.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the transition of the independent registered public accounting firm.
Material Changes
- Resignation of Auditor: Cherry Bekaert LLP resigned as the Company's independent registered public accounting firm effective December 16, 2024.
- Engagement of New Auditor: The Company engaged Salberg & Company P.A. as its new independent registered public accountant for the fiscal year ending December 31, 2024, effective December 18, 2024.
- Audit History: Cherry Bekaert's reports for the years ended December 31, 2023, and 2022 included an explanatory paragraph regarding the Company's ability to continue as a going concern. No adverse, qualified, or modified opinions were issued.
- Internal Controls: Cherry Bekaert previously advised the Company of material weaknesses in its internal control over financial reporting as of December 30, 2023, and 2022.
- Disagreements: There were no disagreements between the Company and Cherry Bekaert regarding accounting principles, practices, or audit scope during the two most recent fiscal years or the subsequent interim period.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or specific risk factors beyond the noted material weaknesses in internal controls and the going concern qualification in prior audit reports. The resignation and engagement were approved by the Audit Committee and the Board of Directors.
Investor Verification Checklist
- Verify the status of the material weaknesses in internal control over financial reporting identified by the prior auditor.
- Review the Company's most recent financial statements to assess the ongoing "going concern" qualification.
- Confirm the transition timeline and any potential impact on the audit of the fiscal year ending December 31, 2024.
- Check for any subsequent filings regarding the Company's liquidity and capital resources given the prior going concern warning.